According to court documents, medical research relevant to the internal bleeding allegations made by plaintiffs in Xarelto lawsuits will be presented to the court, the attorneys and the people on June 11, 2015. This process of pretrial proceedings, known as Science Day, is part of an ongoing national Multidistrict Litigation (MDL) involving allegations of bleeding side effects in patients who used Xarelto.
On Science Day, experts will present their findings on atrial fibrillation, a medical condition for which Xarelto is prescribed. Other medical topics to be presented include the existing record of Xarelto adverse events, clinical trials of Xarelto, and anti-coagulation therapy.
Xarelto was marketed by Janssen Research and Development as a blood-thinning alternative to drugs like warfarin. Warfarin, and other blood-thinning drugs commonly prescribed for years, require frequent testing while using the medication. Xarelto marketing emphasized the lack of testing during use as a major advancement in the freedom of patients needing anti-coagulation (blood-thinning) therapy.
However, plaintiffs in ongoing litigation are alleging that Xarelto makers did not properly warn the public of the risk of uncontrolled bleeding side effects. Side effects, plaintiffs allege that Xarelto drug makers knew or should have known about.